Plasma Cell Neoplasms (Including Multiple Myeloma)—Patient Version - National Cancer Institute

Plasma Cell Neoplasms (Including Multiple Myeloma)—Patient Version - National Cancer Institute







Multiple Myeloma

The FDA recently approved three new drugs for multiple myeloma. To learn more about multiple myeloma, including what it is, how it is treated, statistics, and ongoing research, see our Multiple Myeloma page.

Overview

Plasma cells are cells in the immune system that make antibodies, which help the body fight infection and disease. Plasma cell neoplasms are diseases in which the body makes too many plasma cells in the bone marrow and these cells are abnormal. The abnormal plasma cells make M proteins, which are abnormal antibodies that build up in the bone marrow and can cause the blood to thicken or damage the kidneys.

The abnormal plasma cells can also form tumors in the bone or soft tissue. When there is only one tumor, the disease is called a plasmacytoma. When there is more than one tumor, the disease is called multiple myeloma. Both are malignant (cancer).

Multiple myeloma may not cause signs or symptoms for a long time and is often not found until it is advanced. Myeloma tumors can weaken the bone, cause too much calcium in the blood, and damage the kidneys and other organs. Bone pain is a common symptom of advanced multiple myeloma. Other signs and symptoms include frequent infections, anemia, bleeding, numbness or tingling, and weakness.

One type of benign (not cancer) plasma cell neoplasm is called monoclonal gammopathy of undetermined significance (MGUS). In MGUS, there are low levels of M protein and there are no symptoms or damage to the body. In rare cases, MGUS can become multiple myeloma.

Overview

This Web page provides evidence-based cancer information for health professionals about the treatment of multiple myeloma and other plasma cell neoplasms, as well as resources for supportive and palliative care. Information on multiple myeloma and other plasma cell neoplasms research, such as active clinical trials, clinical trial results, and other research findings, is also provided.

The PDQ® cancer information summaries provide comprehensive, peer-reviewed, evidence-based information intended to inform and assist clinicians who care for cancer patients. The summaries include level-of-evidence designations to help readers understand the strength of the evidence supporting the use of specific interventions or approaches.